| CATEGORY OF SCHEME | Sectoral/Thematic |
| INVESTMENT OBJECTIVE | The investment objective of the scheme is to seek to generate long term capital appreciation through investing in equity and equity related securities of companies engaged in Pharma and Healthcare. However, there can be no assurance that the investment objective of the scheme would be achieved. |
| Inception Date (Date of Allotment): | 08-Nov-21 |
| Benchmark: | Nifty Healthcare TRI |
| Minimum Application Amount: | Rs.5,000/- and in multiples of Rs. 1/- thereafter |
| Load Structure: | Entry Load: Nil Exit Load: If redeemed/Switched out on or before 3 Months from the date of allotment; Exit Load is 0.50% Exit Load after completion of 3 months - NIL |
| Total Expense Ratio (TER): | Regular Plan: 2.39% |
| Fund Manager | Mr. Dhimant Shah (Since 01 December 2022) |
| AUM (in Rs. Cr): | 229.56 |
| AAUM (in Rs. Cr): | 220.02 |
| % of top 5 holdings: | 37.52% |
| % of top 10 holdings: | 56.77% |
| No. of scrips: | 38 |
| Standard Deviation^: | 16.75% |
| Beta^: | 0.93 |
| Sharpe Ratio^*: | 0.85 |
| Average P/B | 9.28 |
| Average P/E | 46.07 |
| Portfolio Turnover Ratio | 0.41 |
| ^Computed for the 3-yr period ended April 30, 2026. Based on monthly return. *Risk free rate: 5.34 (Source: FIMMDA MIBOR) |
|
Regular Plan
(in Rs.) |
Direct Plan
(in Rs.) |
|
| Growth: | 15.9207 | 17.4188 |
| IDCW: | 15.9207 | 17.4168 |
Name of the Instrument |
% to
NAV |
% to NAV
Derivatives |
|
Equity & Equity Related Total |
96.90 |
1.36 |
|
Capital Goods |
0.91 |
||
Standard Engineering Technology Ltd |
0.91 |
||
Chemicals |
2.65 |
||
Linde India Limited |
1.37 |
||
Jubilant Ingrevia Limited |
1.28 |
||
Consumer Durables |
1.29 |
||
Shaily Engineering Plastics Limited |
1.29 |
||
Financial Services |
1.26 |
||
SBI Life Insurance Company Limited |
1.26 |
||
Healthcare |
90.79 |
1.36 |
|
zz |
Sun Pharmaceutical Industries Limited |
12.40 |
1.36 |
zz |
Divi's Laboratories Limited |
8.83 |
|
zz |
Apollo Hospitals Enterprise Limited |
6.25 |
|
zz |
Max Healthcare Institute Limited |
5.22 |
|
zz |
Torrent Pharmaceuticals Limited |
4.82 |
|
zz |
Lupin Limited |
4.44 |
|
zz |
Aurobindo Pharma Limited |
4.36 |
|
zz |
Laurus Labs Limited |
4.24 |
|
zz |
Fortis Healthcare Limited |
3.11 |
|
zz |
Cohance Lifesciences Limited |
3.08 |
|
Neuland Laboratories Limited |
3.05 |
||
Alkem Laboratories Limited |
2.93 |
||
Glenmark Pharmaceuticals Limited |
2.69 |
||
Aster DM Healthcare Limited |
2.24 |
||
Mankind Pharma Limited |
1.91 |
||
Sai Life Sciences Limited |
1.84 |
||
Dr. Reddy's Laboratories Limited |
1.82 |
||
Abbott India Limited |
1.79 |
||
Park Medi World Limited |
1.67 |
||
Cipla Limited |
1.64 |
||
IPCA Laboratories Limited |
1.50 |
||
FDC Limited |
1.21 |
||
Piramal Pharma Limited |
1.20 |
||
Biocon Limited |
1.19 |
||
Healthcare Global Enterprises Limited |
1.09 |
||
Rainbow Childrens Medicare Limited |
0.99 |
||
GlaxoSmithKline Pharmaceuticals Limited |
0.94 |
||
Shilpa Medicare Limited |
0.88 |
||
Poly Medicure Limited |
0.79 |
||
Caplin Point Laboratories Limited |
0.78 |
||
Supriya Lifescience Limited |
0.77 |
||
Zydus Lifesciences Limited |
0.65 |
||
Syngene International Limited |
0.45 |
||
Short Term Debt & Net Current Assets |
1.75 |
|
Top Ten Holdings
| Period | Fund Returns (%) |
Benchmark Returns (%) |
Additional Benchmark Returns (%) |
Benchmark (Rs) |
Fund (Rs) |
Additional Benchmark Returns (Rs) |
Regular - Growth |
||||||
| Last 1 Year | 0.32% | 6.78% | -0.28% | 10,032 | 10,678 | 9,972 |
| Last 3 Years | 19.48% | 23.71% | 11.18% | 17,083 | 18,964 | 13,753 |
| Since Inception | 10.95% | 13.73% | 7.74% | 15,921 | 17,787 | 13,960 |
Direct - Growth |
||||||
| Last 1 Year | 2.23% | 6.78% | -0.28% | 10,223 | 10,678 | 9,972 |
| Last 3 Years | 21.82% | 23.71% | 11.18% | 18,109 | 18,964 | 13,753 |
| Since Inception | 13.20% | 13.73% | 7.74% | 17,419 | 17,787 | 13,960 |
Past performance may or may not be sustained in future and is not a guarantee of any future returns, and should not be used as a basis of comparison with other investments. The performance data for 5 years period has not been provided, since scheme is in existence for less than 5 years. In case, the start / end date of the concerned period is a non-business date (NBD), the NAV of the previous date is considered for computation of returns. Different Plans i.e. Regular Plan and Direct Plan under the scheme have different expense structure. Benchmark: Nifty Healthcare TRI Additional Benchmark: Nifty 50 TRI. Fund Managers: Mr. Dhimant Shah (Managing since 01-December-22). Inception date of the scheme is (08-Nov-2021). Face Value per unit: Rs. 10. ITI Pharma & Healthcare Fund NAV as on April 30, 2026: Rs. 15.9207 (Regular Growth Option), Rs. 17.4188 (Direct Growth Option)
| Period | Amount Invested |
Fund Returns (%) |
Benchmark Returns (%) |
Additional Benchmark Returns (%) |
Fund Value () |
Benchmark Value () |
Additional Benchmark Value () |
Regular - Growth |
|||||||
| Last 1 Year | 1,20,000 | 1.58% | 7.68% | -6.15% | 1,21,013 | 1,24,875 | 1,16,014 |
| Last 3 Years | 3,60,000 | 9.33% | 14.17% | 4.61% | 4,14,058 | 4,44,155 | 3,86,096 |
| Since Inception | 5,40,000 | 12.81% | 16.59% | 7.86% | 7,20,049 | 7,82,374 | 6,45,125 |
Direct - Growth |
|||||||
| Last 1 Year | 1,20,000 | 3.48% | 7.68% | -6.15% | 1,22,225 | 1,24,875 | 1,16,014 |
| Last3 Years | 3,60,000 | 11.50% | 14.17% | 4.61% | 4,27,377 | 4,44,155 | 3,86,096 |
| Since Inception | 5,40,000 | 15.08% | 16.59% | 7.86% | 7,56,938 | 7,82,374 | 6,45,125 |
Past performance may or may not be sustained in future and is not a guarantee of any future returns, and should not be used as a basis of comparison with other investments. Different Plans i.e. Regular Plan and Direct Plan under the scheme have different expense structure. Benchmark: Nifty Healthcare TRI Additional Benchmark: Nifty 50 TRI. For SIP returns, monthly investment of Rs.10,000 invested on the 1st business day of every month has been considered. CAGR Returns (%) are computed after accounting for the cash flow by using the XIRR method (investment internal rate of return).
THIS PRODUCT IS SUITABLE FOR INVESTORS WHO ARE SEEKING^
^Investors should consult their financial advisers if in doubt about whether the product is suitable for them.


Face Value per Unit: Rs. 10 unless other wise specified; Data is as of April 30, 2026 unless other wise specified.
Mutual Fund investments are subject to market risks, read all scheme related documents carefully